Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Lung Cancer Video Library - Spanish Language: Video #44 Treatment of Stage III Unresectable Non-Small Cell Lung Cancer
Author
Denise Brock
 
 

 

We are pleased to continue this series of informational videos for our Spanish speaking community.  GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance.  In this 44th video for the Spanish lung cancer video library, Dr. Santana-Davila joined GRACE to discuss the treatment of stage 3 unresectable non-small cell lung cancer.

 

 

Tratamiento de Cancer de Pulmón de Células no Pequeñas en Estadio Tres no Resecable

Treatment of Stage III Nonresectable Non-Small Cell Lung Cancer

 

Assistant Professor of Medicine
University of Washington Seattle Cancer Care Alliance
Seattle, Washington

 

Spanish TRANSCRIPT

Cuando el paciente se encuentra en estadio tres y no es candidato a cirugía porque el cancer está en varios ganglios del mediastino o por otras razones, lo que hacemos es quimioterapia con radiación al mismo tiempo. La radiación se da todos los días por cuatro a seis semanas y la quimioterapia dependiendo de qué régimen se escoge puede ser una vez por semana o dos ciclos de quimioterapia durante la radiación.

Para saber cuál quimioterapia es mejor es un poco controversial, pero depende mucho de la plática que se tiene con el paciente para conocer el tiempo que se tiene, los beneficios y riesgos. Los regímenes que son más comunes en Estados Unidos son carboplatino con paclitaxel una vez por semana. Una vez que se acaban las cuatro a seis semanas de radiación, se dan otros dos ciclos que se llaman ciclos de consolidación. El otro régimen que es muy común es cisplatino con etopósido y esto se da dos ciclos de quimioterapia durante la radiación sin hacer quimioterapias adicionales.


  

English TRANSCRIPT

When the patient is in stage three and is not a candidate to surgery because the cancer is in some lymph nodes of the mediastinum or other reasons, the best option is chemotherapy with radiation at the same time. The radiation is given every day for four to six weeks and the chemotherapy, depending on the regimen chosen, can be once per week or two cycles of chemotherapy during the entire treatment of radiation.

The types of chemotherapies are controversial because to choose which one is better depends on the discussion you have with your doctor to know the time they have, the risks and benefits. The most common regimens in United States are carboplatin and paclitaxel once per week. Once the four to six weeks are over, two more cycles of radiation are given to consolidate. The other common regimen is cisplatin with etoposide, they are given in two cycles of chemotherapy during the radiation with no additional chemotherapies.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on